

CURRICULUM VITAE

Carol Louik, Sc.D.

Date of Birth: June 24, 1947

EDUCATION:

- 2/79 - 11/83 Harvard School of Public Health
Sc.D. in Epidemiology
- 9/74 - 3/77 Harvard School of Public Health
M.S. in Biostatistics
- 9/65 - 6/69 Brandeis University
B.A. in Mathematics

EMPLOYMENT:

- 2001- Slone Epidemiology Center, Boston University School of Medicine
Senior Epidemiologist
- 1988 - 2001 Slone Epidemiology Unit, Boston University School of Medicine
Senior Epidemiologist
- 1985 - 1987 Epidemiology Resources, Inc., Staff Epidemiologist
- 1985 - 1986 Assistant Research Professor of Epidemiology, School of Public Health, Boston
University School of Medicine
- 11/79 - 85 Drug Epidemiology Unit, Boston University School of Medicine
Senior Epidemiologist
- 9/80 - 6/82 Department of Epidemiology, Harvard School of Public Health Teaching Fellow
- 10/76 - 10/78 Department of Epidemiology, Harvard School of Public Health Project
Coordinator
- 4/75 - 6/76 Department of Epidemiology, Harvard School of Public Health Applications
Programmer
- 2/72 - 4/75 Boston Collaborative Drug Surveillance Program, Boston University Medical
Center, Programmer

ABSTRACTS:

1. Mitchell AA, Louik C, Gute DM. Accutane exposure in pregnancy--A novel survey design. *Teratology* 1990;41:578.
2. Werler MM, Louik C, Mitchell AA. Heat source exposure and neural tube defect risk. Society for Epidemiology Research, June 22-24, 1995, Snowbird, Utah.
3. Louik C, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. Society for Epidemiology Research, June 24, 1995, Snowbird, Utah.
4. Mitchell AA, Louik C, Werler MM. Secular trends in medication use in pregnancy. Society for Pediatric Epidemiology Research, June 21, 1995, and Society for Epidemiology Research, June 23, 1995, Snowbird, Utah.
5. Werler MM, Louik C, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects in offspring. Teratology Society, June 28, 1995, Newport Beach, California.
6. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of risk factors for amniotic bands. *Teratology* 1999;59:388.
7. Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Relative risk of preeclampsia in pregnancies supported by infertility treatments. *Pharmacoepidemiol Drug Saf* 2003;12:S3.
8. Louik C, Mitchell AA. Post-Marketing Surveillance using Pharmacy-based Cohorts. *Pharmacoepidemiol Drug Saf* 2003;12:S96.
9. Louik C, Werler MM, Hernández-Díaz S, Mitchell AA. Use of herbal treatments in pregnancy. *Pharmacoepidemiol Drug Saf* 2003;12:S113-4.
10. Louik C, Hernández-Díaz S, Werler MM, Mitchell AA. Do We Need Bendectin? Trends in the Use of Anti-Emetics Since 1976 in the US and Canada. *Pharmacoepidemiol Drug Saf* 2004;13:S136. International Society for Pharmacoepidemiology, August 24, 2004, Bordeaux, France.
11. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First trimester exposure to SSRIs and the risk of birth defects. *Pharmacoepidemiol Drug Saf* 2006;15:S81-2.
12. Louik C, Kelly JP, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Accuracy of recall of recent medication use. *Pharmacoepidemiol Drug Saf* 2006;15:S283-4.
13. Louik C, Schatz M, Hernández-Díaz S, Werler MM, Mitchell AA. Revisiting the steroids-oral cleft controversy. *Pharmacoepidemiol Drug Saf* 2007;16:S39-40.
14. Louik C, Werler MM, Mitchell AA. Antifungal medications and the risk of hypoplastic left heart syndrome. *Pharmacoepidemiol Drug Saf* 2008;17:S14.

15. Louik C, Chambers C, Mitchell AA. Vaccine safety in pregnancy: Can we identify exposures? *Pharmacoepidemiol Drug Saf* 2008;17:S226-7.

LETTERS-TO-THE-EDITOR:

1. Louik C, Mitchell AA. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis [letter to the editor]. *Obstet Gynecol* 2003;101(4):816.

PUBLICATIONS:

1. Rothman KJ, Louik C. Oral contraceptives and birth defects. *N Engl J Med* 1978;299:522-4.
2. Delzell ES, Louik C, Monson RR, Lewis J. Mortality and cancer morbidity in the tire industry. *Am J Ind Med* 1981;2:209-16.
3. Mitchell AA, Louik C, Lacouture P, Slone D, Goldman P, Shapiro S. Risks to children from computed tomographic scan premedication. *J Am Med Assoc* 1982;247:2385-8.
4. Rosenberg L, Mitchell AA, Parsells J, Pashayan H, Louik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. *N Engl J Med* 1983;309:1282-5.
5. Mitchell AA, Schwingl PJ, Rosenberg L, Louik C, Shapiro S. Birth defects in relation to Bendectin use in pregnancy: pyloric stenosis. *Am J Obstet Gynecol* 1983;147:737-42.
6. Louik C, Mitchell AA, Epstein MF, Shapiro S. Risk factors for neonatal hyperglycemia associated with 10% dextrose infusion. *Am J Dis Child* 1985;139:783-6.
7. Louik C, Lacouture PG, Mitchell AA, Kauffman R, Lovejoy FH, Yaffe SJ, Shapiro S. A study of adverse reaction algorithms in a drug surveillance program. *Clin Pharmacol Ther* 1985;38:183-7.
8. Lesko S, Mitchell AA, Epstein MF, Louik C, Giacoia GP, Shapiro S. Heparin use as a risk factor for intraventricular hemorrhage in low-birth-weight infants. *N Engl J Med* 1986;314:1156-60.
9. Louik C, Mitchell A, Werler M, Hanson J, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. *N Engl J Med* 1987;317:474-8.
10. Werler MM, Louik C, Shapiro S, Mitchell AA. Ovulation induction and risk of neural tube defects. *Lancet* 1994;344:445-6.
11. Mitchell AA, Van Bennekom C, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. *N Engl J Med* 1995;333:101-6.
12. Werler MM, Louik C, Shapiro SS, Mitchell AA. Prepregnant weight in relation to risk of neural tube defects. *J Am Med Assoc* 1996;275:1089-92.

13. Rosenberg L, Louik C, Shapiro S. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel carcinoma. *Cancer* 1998;82:2326-33.
14. Lesko SM, Louik C, Vezina R, Rosenberg L, Shapiro S. Vasectomy and prostate cancer. *J Urol* 1999;161:1848-53.
15. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150:675-82.
16. Werler MM, Louik C, Mitchell AA. Achieving a public health recommendation for preventing neural tube defects with folic acid. *Am J Public Health* 1999;89:1637-40.
17. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. *Cancer Causes Control* 2000;11:249-55.
18. Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg L. A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. *Cancer Epidemiol Biomarkers Prev* 2000;9:443-7.
19. Louik C, Frumkin H, Ellenbecker MJ, Goldman RH, Werler MM, Mitchell AA. Use of a job-exposure matrix to assess occupational exposures in relation to birth defects. *J Occup Environ Med* 2000;42:693-703.
20. Lesko SM, Louik C, Vezina RM, Mitchell AA. Asthma morbidity after the short-term use of ibuprofen in children. *Pediatrics* 2002;109:e20.
21. Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. *Am J Obstet Gynecol* 2002;186:288-90.
22. Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Risk of gestational hypertension in relation to folic acid supplementation during pregnancy. *Am J Epidemiol* 2002;156:806-12.
23. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors and amniotic band defects. *Birth Defects Res A Clin Mol Teratol* 2003;67:68-72.
24. de Jong-van den Berg LTW, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Trends and predictors of folic acid awareness and periconceptional use in pregnant women. *Am J Obstet Gynecol* 2005;192:121-8.
25. Louik C, Mitchell AA. Post-marketing surveillance using pharmacy-based cohorts: results of a pilot study. *Pharmacoepidemiol Drug Saf* 2005;14:289-95.
26. Chambers CD, Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354(6):579-87.

27. Louik C, Hernández-Díaz S, Werler MM, Mitchell AA. Nausea and vomiting in pregnancy: maternal characteristics and risk factors. *Paediatr Perinat Epidemiol* 2006;20:270-8.
28. Meijer WM, Werler MM, Louik C, Hernández-Díaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down syndrome? *Birth Defects Res A Clin Mol Teratol* 2006;76(10):714-7.
29. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med* 2007;356:2675-83.
30. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. *Pediatrics* 2007;120(2):272-82.
31. Shaw GM, Carmichael SL, Laurent C, Louik C, Finnell RH, Lammer EJ, and the National Birth Defects Prevention Study. Nutrient intakes in women and risks of anophthalmia and microphthalmia in their offspring. *Birth Defects Res A Clin Mol Teratol* 2007;79(10):708-13. doi: 10.1002/bdra.20398.
32. Bitsko RH, Reefhuis J, Louik C, Werler MM, Feldkamp ML, Waller DK, Frias J, Honein MA, and the National Birth Defects Prevention Study. Periconceptional use of weight loss products including Ephedra and the association with birth defects. *Birth Defects Res A Clin Mol Teratol* 2008;82(8):553-62.
33. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA, and the National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: a case-series approach [research letter]. *Am J Med Genet A* 2008;146A(20):2701-5. doi: 10.1002/ajmg.a.32493.
34. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernández-Díaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. *Am J Psychiatry* 2009;166:320-8. doi: 10.1176/appi.ajp.2008.08060817. PMID: PMC2735348.
35. Toh S, Mitchell AA, Louik C, Werler MM Chambers CD, Hernández-Díaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. *J Clin Psychopharmacol* 2009;29(6):555-60. doi: 10.1097/JCP.0b013e3181bf344c. PMID: PMC3206605.
36. Waller DK, Gallaway MS, Shayne M, Taylor LG, Ramadhani TA, Canfield MA, Scheuerle A, Hernández-Díaz S, Louik C, Correa A, and the National Birth Defects Prevention Study. Use of oral contraceptives in pregnancy and major structural birth defects in offspring. *Epidemiology* 2010;21(2):232-9. doi: 10.1097/EDE.0b013e3181c9fbb3.
37. Broussard CS, Louik C, Honein MA, Mitchell AA. Herbal use before and during pregnancy. *Am J Obstet Gynecol* 2010;202:443.e1-6. doi: 10.1016/j.ajog.2009.10.865.
38. Louik C, Gardiner P, Kelley K, Mitchell AA. Use of herbal treatments in pregnancy. *Am J Obstet Gynecol* 2010;202(5):439.e1-10. PMID: PMC2867842.

39. Louik C, Schatz M, Hernández-Díaz S, Werler MM, Mitchell AA. Asthma in pregnancy and its pharmacologic treatment. *Ann Allergy Asthma Immunol* 2010;105:110-7. PMID: PMC2953247.
40. Schatz M, Chambers CD, Jones KL, Louik C, Mitchell AA. The safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. *Am J Obstet Gynecol* 2011;204(6 Suppl. 1):S64-8. doi: 10.1016/j.ajog.2011.01.047.
41. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, and the National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *Am J Obstet Gynecol* 2011;205:51.e1-8. doi: 10.1016/j.ajog.2011.02.029. PMID: PMC3793635.
42. Werler MM, Louik C, Mitchell AA. Case-control studies for identifying novel teratogens. *Am J Med Genet C Semin Med Genet* 2011;157:201-8. doi: 10.1002/ajmg.c.30307. PMID: PMC3483035.
43. Yau WP, Lin KJ, Werler MM, Louik C, Mitchell AA, Hernández-Díaz S. Drug certainty-response in interview-based studies. *Pharmacoepidemiol Drug Saf* 2011;20:1210-6. doi: 10.1002/pds.2234. PMID: PMC3222943.
44. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Díaz S, Rasmussen SA, and the National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol* 2012;94(1):22-30. doi: 10.1002/bdra.22865. PMID: PMC3299087.
45. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Maternal exposure to amoxicillin and the risk of oral clefts. *Epidemiology* 2012;23(5):699-705. doi: 10.1097/EDE.0b013e318258cb05. PMID: PMC3729019.
46. Ahrens K, Lash TL, Louik C, Mitchell AA, Werler MM. Correcting for exposure misclassification using survival analysis with a time-varying exposure. *Ann Epidemiol* 2012;22:799-806. doi: 10.1016/j.annepidem.2012.09.003. PMID: PMC3489973.
47. Louik C, Chambers C, Jacobs D, Rice F, Johnson D, Mitchell AA. Influenza vaccine safety in pregnancy: can we identify exposures?. *Pharmacoepidemiol Drug Saf* 2013;22:33-9. doi: 10.1002/pds.3336.
48. Van Marter LJ, Hernández-Díaz S, Werler MM, Louik C, Mitchell AA. Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. *Pediatrics* 2013;131:79-87. doi: 10.1542/peds.2012-0496. PMID: PMC3529942.
49. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. *Am J Obstet Gynecol* 2013;208(3):221.e1-8. doi: 10.1016/j.ajog.2012.12.023. PMID: PMC3581717.

50. Louik C, Ahrens K, Kerr S, Pyo J, Chambers C, Jones KL, Schatz M, Mitchell AA. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects. *Vaccine* 2013;31(44):5033-40. doi: 10.1016/j.vaccine.2013.08.096.
51. Chambers CD, Johnson D, Xu R, Luo Y, Louik C, Mitchell AA, Schatz M, Jones KL, and the OTIS Collaborative Research Group. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. *Vaccine* 2013;31(44):5026-32. doi: 10.1016/j.vaccine.2013.08.097.
52. Browne ML, Van Zutphen AR, Botto LD, Louik C, Richardson S, Druschel CM. Maternal butalbital use and selected defects in the National Birth Defects Prevention Study. *Headache* 2014;54(1):54-66. doi: 10.1111/head.12203.
53. Yazdy MM, Mitchell AA, Louik C, Werler MM. Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot. *Epidemiology* 2014;25(6):859-65. doi: 10.1097/EDE.000000000000157. PMID: PMC4180776.
54. Louik C, Kerr S, Mitchell AA. First-trimester exposure to bupropion and risk of cardiac malformations. *Pharmacoepidemiol Drug Saf* 2014;23(10):1066-75. doi: 10.1002/pds.3661.
55. Ahrens KA, Louik C, Kerr S, Mitchell AA, Werler MM. Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small-for-gestational age birth. *Paediatr Perinat Epidemiol* 2014;28(6):498-509. doi: 10.1111/ppe.12152. PMID: PMC Journal – In Process.
56. van Gelder MM, Van Bennekom CM, Louik C, Werler MM, Roeleveld N, Mitchell AA. Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. *Br J Obstet Gynaecol* 2015;122:1002-9. doi: 10.1111/1471-0528.13138.
57. Louik C, Kerr S, Kelley KE, Mitchell AA. Increasing use of ADHD medications in pregnancy [letter to the editor]. *Pharmacoepidemiol Drug Saf* 2015;24(2):218-20. doi: 10.1002/pds.3742. PMID: PMC4313616.
58. Yazdy MM, Mitchell AA, Louik C, Werler MM. The authors respond [letter to the editor]. *Epidemiology* 2015;26(3):e35-6. doi: 10.1097/EDE.0000000000000281. PMID: PMC4388046.
59. Mitchell AA, Louik C, Chambers C, Jones KL, Schatz M. Immunization surveillance systems for pregnant women [letter to the editor]. *Pharmacoepidemiol Drug Saf* 2015;24:669. doi: 10.1002/pds.3784.
60. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, and the National Birth Defects Prevention Study. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. *BMJ* 2015;351:h3190. doi: 10.1136/bmj.h3190.
61. Louik C, Werler MM, Anderka M, Mitchell AA. Application of data screening to drug exposure in large risk factor studies of birth defects. *Birth Defects Res A Clin Mol Teratol* 2015;103(8):713-7. doi: 10.1002/bdra.23407.

cv_cl.doc (9/4/2015)